Unlocking the Value of RWE in Drug Pricing Decisions

As drug pricing becomes more outcomes-driven, real-world evidence (RWE) is emerging as a critical lever in shaping access and reimbursement decisions. Yet for many manufacturers, RWE remains underutilized—applied too late to influence pricing strategy.

In this featured presentation from the 2025 Evidence 360 Summit, Magnolia Market Access’s Beni Turner explores how RWE can be strategically integrated across the product lifecycle to drive more effective pricing and access outcomes.

Why It Matters

Global regulators and HTA bodies are accelerating the use of RWE to evaluate value, inform reimbursement, and shape coverage decisions. Biopharma companies that embed RWE early and often can more effectively support value narratives, negotiate contracts, and respond to pricing pressures.

What You’ll Learn

This presentation highlights:

• The regulatory shift toward formal RWE frameworks in the U.S. and Europe
• Key payer considerations—budget impact, population relevance, and real-world adherence
• Common barriers to RWE adoption and how to address them
• Innovations in RWD blending, including SDoH and patient-reported outcomes
• A framework for building RWE-driven pricing strategies across medical, HEOR, and market access teams

Featured Presenter

Beni Turner

Director, Real World Clinical Insights,
Magnolia Market Access

Evidence 360: RWE, Pricing & Reimbursement Summit USA 2025, Philadelphia, PA

Download